Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 7/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862599 | 0.85 | HDAC4 (0.39) | SIGMAR1DRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22862777 | 0.83 | KDM4E (0.37) | — | |
| SCHEMBL22862654 | 0.83 | HDAC4 (0.39) | SIGMAR1DRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22862438 | 0.83 | ALDH1A1 (0.40) | QPCT | |
| SCHEMBL22862469 | 0.81 | CYP11B1 (0.39) | SIGMAR1CDK9BRD4DPP4 | |
| SCHEMBL22862463 | 0.81 | CYP11B1 (0.44) | BRD4 | |
| SCHEMBL22862658 | 0.80 | MAPK14 (0.37) | SIGMAR1DRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22862595 | 0.78 | LMNA (0.39) | SIGMAR1DRD4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22862994 | 0.76 | KDM4E (0.37) | — | |
| SCHEMBL22862770 | 0.76 | KDM4E (0.33) | SIGMAR1CDK9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| EP-3976009-A2 | BAX INHIBITORS AND USES THEREOF | Case Western Reserve University (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | SIGMAR1 3942/4885DRD4 4762/4885CACNA1G 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.